CA-SYNACK
13.6.2019 15:02:06 CEST | Business Wire | Press release
The debate on how we should best use Artificial Intelligence is ongoing, but no one can argue against its benefits when used to augment human work. Take self-driving cars: when Artificial Intelligence is used alongside humans, it provides features like improved safety and predictive driving. The same is true in cybersecurity; we will always need the creativity of human intelligence to beat the human adversary. However, we can also augment those humans with smart technology to help make them more effective, cover a wider attack surface, and speed up their time to find and fix vulnerabilities. Synack, the trusted leader in crowdsourced security, has just launched the industry’s first cybersecurity platform to integrate crowdsourced human intelligence augmented with artificial intelligence to help security teams work smarter, not harder, to protect digital assets continuously and at scale.
The impact? Intelligence that helps security teams find and fix vulnerabilities faster and build more secure code.
The stakes are high - cybercrime is predicted to cost the world $6 trillion annually by 2021- and human capital to protect the cybersphere is lacking; 3.5 million cybersecurity jobs are predicted to go unfilled by 2021 (Cybersecurity Ventures).
“While humans can’t scale, machines can’t think. More than 80% of the vulnerabilities that our Synack Red Team find in our clients’ assets aren’t detected by a scanner. We will always need the creativity of human intelligence. But to scale at the pace of the threats, we need to automate wherever possible and keep building technology to test ‘smarter’,” Dr. Mark Kuhr, Synack CTO and co-founder said.
Synack’s industry-leading cybersecurity Platform 2.0 delivers a smarter, more efficient security test through the use of smart platform technology and new product, SmartScan. Together, the platform’s new features and advanced technology seamlessly orchestrate the optimal combination of human and machine intelligence for more effective, efficient security on a 24/7/365 basis. SmartScan helps security teams increase their attack surface coverage and gain new insight by continuously scanning for suspected vulnerabilities and engaging the company’s crowdsourced network of ethical hackers to validate them. The augmented intelligence offered by Synack’s “smart” Crowdsourced Security Platform, if applied to all penetration testing, would add 4x more efficiency to security teams.
Additional benefits of Synack’s Crowdsourced Security Platform to security teams include:
- Noise Reduction: 99.98% of total noise is reduced by leveraging Synack SmartScan in combination with Synack Red Team crowdsourced vulnerability triage and patch verification services.
- Higher Value: The latest version of Synack’s platform with augmented intelligence increases the ROI of Synack’s original offering by over 50%. Customers will see a 159% ROI with the Synack Crowdsourced Security Platform in comparison to a traditional penetration test. And if comparing the Synack platform to a traditional scanner, they will get a 262% ROI. If deployed universally across application security testing, SmartScan would add ~$3B in security value back to the market.
In addition to SmartScan, Synack’s Crowdsourced Security Platform 2.0 includes other new and enhanced features; Apollo, a machine learning and automation engine that optimizes the integration of humans and technology, superior analytics and reporting, and LaunchPoint+, a secure testing gateway with added researcher endpoint control and enhanced workspaces to support privacy for highly regulated environments. Synack Red Team researchers said they were “happy with the [LaunchPoint+] concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot” in response to Synack launching the only crowdsourced security testing with endpoint control baked into the platform.
About Synack
Synack, the most trusted crowdsourced security platform, delivers continuous and scalable penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create an efficient and effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005222/en/
Contact:
Ellie McCardwell, Synack Communications press@synack.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom